Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
rituximab + pegylated interferon α-2b
- Development stage
- Unknown
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Administration
- Intravenous, Subcutaneous
01
Overview
**Rituximab + pegylated interferon α-2b** is a combination regimen investigated for the treatment of advanced indolent B-cell non-Hodgkin lymphoma (NHL) and severe hepatitis C virus (HCV)-related vasculitis. Rituximab, a chimeric monoclonal antibody, targets the CD20 antigen on B-lymphocytes, inducing cell lysis via antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and apoptosis. Pegylated interferon α-2b, a modified cytokine, enhances antiviral and immunomodulatory effects by activating the JAK-STAT pathway, promoting interferon-stimulated gene expression to inhibit viral replication and boost immune responses. Preliminary phase 2 data show the combination is well-tolerated in untreated advanced indolent B-cell NHL, with rituximab biosimilars demonstrating comparable efficacy.
- Brand names
- HenlirituxPegberon
- Other names
- rituximab biosimilar + pegylated interferon α-2b
02
Targets
CD20 (B-lymphocyte antigen CD20)IFNAR (Immune system modulation via type I interferon receptor)
Beyond the preview
Go deeper on rituximab + pegylated interferon α-2b.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on rituximab + pegylated interferon α-2b.